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Abstract
Background: The SRY-related HMG-box family of transcription factors member SOX2 has been mainly studied in
embryonic stem cells as well as early foregut and neural development. More recently, SOX2 was shown to
participate in reprogramming of adult somatic cells to a pluripotent stem cell state and implicated in
tumorigenesis in various organs. In breast cancer, SOX2 expression was reported as a feature of basal-like tumors.
In this study, we assessed SOX2 expression in 95 primary tumors of postmenopausal breast cancer patients.
Methods: Samples from 95 patients diagnosed and treated at the University of Tuebingen Institute of Pathology
and Women’s Hospital were analyzed by immunohistochemistry for SOX2 expression in the primary tumor samples
and in corresponding lymph node metastasis, where present. Furthermore, SOX2 amplification status was assessed
by FISH in representative samples. In addition, eighteen fresh frozen samples were analyzed for SOX2, NANOG and
OCT4 gene expression by real-time PCR.
Results: SOX2 expression was detected in 28% of invasive breast carcinoma as well as in 44% of ductal carcinoma in
situ (DCIS) lesions. A score of SOX2 expression (score 0 to 3) was defined in order to distinguish SOX2 negative (score
0) from SOX2 positive samples (score 1-3) and among latter the subgroup of SOX2 high expressors (score 3 > 50%
positive cells). Overall, the incidence of SOX2 expression (score 1-3) was higher than previously reported in a cohort
of lymph node negative patients (28% versus 16.7%). SOX2 expression was detected across different breast cancer
subtypes and did not correlate with tumor grading. However, high SOX2 expression (score 3) was associated with
larger tumor size (p = 0.047) and positive lymph node status (0.018). Corresponding metastatic lymph nodes showed
higher SOX2 expression and were significantly more often SOX2 positive than primary tumors (p = 0.0432).
Conclusions: In this report, we show that the embryonic stem cell factor SOX2 is expressed in a variety of early
stage postmenopausal breast carcinomas and metastatic lymph nodes. Our data suggest that SOX2 plays an early
role in breast carcinogenesis and high expression may promote metastatic potential. Further studies are needed to
explore whether SOX2 can predict metastatic potential at an early tumor stage.
Background
Pluripotency-associated transcription factors like
NANOG, SOX2 and OCT4 are known as regulators of
cellular identity in embryonic stem cells and more
recently have been identified in tumors of various ori-
gins. Consistent with their role in sustaining stemness of
embryonic stem cells, pluripotency-related factors have
been suggested to be expressed with higher frequency in
tumors displaying lower degrees of differentiation [1].
In the current study, breast tumor samples were
examined for expression of SOX2 (short for Sex determ-
ing Region Y - box 2), a High Mobility Group (HMG)
domain transcription factor located at chromosome
3q26.33 and member of the SRY-related HMG-box
(SOX) family of transcription factors [2]. SOX proteins
play critical roles during organogenesis and in the
embryonic development of several tissues. Their expres-
sion displays a restricted spatial-temporal pattern. For
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cells blocks their differentiat i o n ,a n dc o n v e r s e l y ,d e p l e -
tion of Sox2 in neural stem cells causes their premature
exit from the cell cycle and respectively differentiation
into neurons [3,4]. In the foregut, Sox2 is a key regula-
tor of embryonic development and expression is found
in all endodermal cells of the undivided foregut. During
bronchogenesis in the developing lung, Sox2 is precisely
regulated and forced overexpression of Sox2 leads to a
block of airway branching [5].
Consistent with the hypothesis that stemness and
embryonic pathways may reactivate during oncogenesis,
SOX family members have been found to be deregulated
in a variety of tumors [4]. SOX2 was detected as an
immunogenic antigen in a significant percentage of
small cell lung cancer patients [6] and meningeoma
patients [7]. In the pancreas, SOX2 expression has been
involved in invasion and metastasis of pancreatic intrae-
pithelial neoplasia [8]. Furthermore, SOX2 was also
shown to be expressed in gastric [9] and prostate can-
cers [10] and more recently, was identified as a lineage-
survival oncogene in squamous cell carcinomas of the
lung [11,12]. However, the significance of SOX2 expres-
sion and its role in different cancers requires further
research since the transcriptional activity of SOX pro-
teins depends on the recruitment of protein partners
and thus profound functional differences may occur in
distinct tissues of origin [13].
To our knowledge, there is no data reporting a role of
SOX2 in breast organogenesis or function. Adult healthy
breast tissue does not show significant SOX2 expression
[14]. However, SOX2 expression was detected in a sub-
group of patients with breast tumors [15], supporting
the notion that in the breast, activation of SOX2 is part
of the malignant progression [14,15]. An active role for
SOX2 during mammary tumorigenesis is further sup-
ported by data collected in breast cancer cell lines,
where SOX2 drives cell proliferation and in vivo tumori-
genesis, partially by facilitating the G1/S transition and
regulating, in concert with b-catenin, the expression of
downstream effector genes such as CCND1 [14,15].
In this report, we analyze the expression of SOX2 in a
cohort of 95 sporadic postmenopausal early-breast can-
cers with respect to clinicopathological factors.
Methods
Tumor Samples
We analyzed a group of 86 sporadic invasive early-stage
breast carcinomas and nine ductal in situ carcinoma
(DCIS) diagnosed and treated at the Institute of Pathol-
ogy and respectively the Women’s University Hospital
Tuebingen. All tissue samples were derived from a series
of consecutive cases at the Department of Pathology ana-
lyzing the differences of clinicopathological factors
between screening-carcinomas and carcinomas detected
outside the screening programme in the same age group.
The age of patients ranged therefore from 50 to 69 years
and all were diagnosed between March 31
st 2008 and
January 19
th 2009. From this group a randomly selected
subset of 86 cases with available paraffin material was
included in this retrospective study. Breast cancer sub-
types were defined by immunohistochemistry profiles as
previously described [16]. Further clinicopathological
characteristics of the cohort are summarized in Table 2.
Furthermore, fresh frozen tissue samples were collected
prospectively from eighteen patients undergoing diagno-
sis and treatment in 2009 and 2010 at the Women’s Uni-
versity Hospital Tuebingen and used for gene expression
analysis as described below.
The study was approved by the institutional Ethics
Review Board of the University Hospital Tuebingen.
Human pluripotent stem cells cultures
The human induced pluripotent stem cell line hFib2-
iPS5 kindly provided by George Q. Daley and In-Hyun
Park, Children’s Hospital Boston [17], was used and
grown in undifferentiated state according to previously
published protocols [17,18].
Immunohistochemistry
Immunohistochemistry was performed with the Ventana
Discovery automated immunostaining system (Ventana
Medical Systems, Tucson, AZ, USA), using Ventana
reagents. Paraffin sections (5 μm) were mounted on
superfrost slides, deparaffinized in inorganic buffer, and
pretreated with EDTA-based buffer (pH 8.4). Primary
antibody (polyclonal goat anti-human SOX2 antibody,
AF2018, R&D systems, dilution 1:40, heat induced epi-
tope retrieval (HIER)) was applied to assess for SOX2
protein expression status. Dilution was performed with
Ventana diluent. Bound antibody was visualized using a
biotinylated detection kit based on diaminobenzidine
and horseradish peroxidase (DABMap-kit, Ventana).
Slides were counterstained with hematoxylin and Blue-
ing Reagent (Ventana). Subsequently, sections were
washed, dehydrated in a graded alcohol series and cov-
ered with Cytoseal. Only nuclear staining was consid-
ered positive and scored by a pathologist according to
published criteria using a semiquantitative score: score
0: no positive cells, score 1: >0 to 10%, score 2 ≥ 10%,
score 3 ≥ 50% [19] (Figure 1A-E). As positive controls
were used samples of squamous cell carcinoma of the
lung [20].
SOX2 amplification fluorescence in-situ hybridization
assay
To assess for SOX2 amplification status at the chromo-
somal level, we applied the same two-color interphase
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probe spanning the locus 3q26.33 (BAC clone CTD-
2348H10) was applied to detect SOX2 copy number sta-
t u sa n dw a sc o m p a r e dt oar e f e rence probe hybridizing
to 3p22.3-3p22.2 (BAC clone RP11-286G5) (both clones
were purchased from Invitrogen, Carlsbad, CA, USA).
The target probe was labelled with biotin and detected
with a streptavidin-conjugated red fluorochrome (SAV-
Alexa Fluor-594, Invitrogen). The reference probe was
labelled with digoxigenin and detected via an anti-digox-
igenin-conjugated green fluorochrome (FITC, Roche,
Basel, Switzerland).
Figure 1 Immunohistochemical staining of SOX2 shows different expression levels in early-stage breast carcinoma samples.
(A) Classification of SOX2 expression in different scores. (B) Staining of normal breast tissue as control. (C) Breast tumor tissue that shows no
positive staining for SOX2 are part of Score 0. (D) Tumor samples with > 0% and < 10% are referred to Score 1. (E) Score 2 samples show ≥ 10%
and < 50% positive stained cells. (F) Samples demonstrating ≥ 50% positive cells belong to Score 3. Pictures were taken with 200X magnification.
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formed semiquantitatively by comparing the number of red
signals (SOX2 target region, respectively) to the number of
corresponding green signals (reference region). A non-
amplified nucleus showed one red target signal for every
corresponding green reference signal, with a red/green ratio
of 1:1. TMA slides were analyzed under a 63x oil immer-
sion objective using a fluorescence microscope (Zeiss, Jena,
Gemany) equipped with appropriate filters. At least 100
nuclei per case were assessed. Cases were included into the
analysis if there was at least one core assessable.
Gene expression analysis
Total RNA from fresh frozen tissue samples was isolated
using RNA isolation kit from Qiagen according to the
manufacturer’s instructions, including Dnase I treatment
to remove contaminating genomic DNA (Invitrogen).
Purified RNA samples were used for RT reaction con-
taining oligo d(pT)18 primers and Superscript II RT
enzyme (Invitrogen) according to the supplier’s protocol.
The synthesis of cDNA was carried out for 50 min at 42°
C followed by 10 min at 70°C to inactivate the RT
enzyme. The amplification of SOX2, NANOG, OCT4, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
genes in the subsequent RT-PCR was achieved with the
following primer pairs (Sigma) and probes (Roche): For
SOX2 (75 bp): 5’-ttgctgcctctttaagactagga-3’,5 ’-
ctggggctcaaacttctctc-3’, and Probe #35; for NANOG (103
bp): 5’-atgcctcacacggagactgt-3’,5 ’-aagtgggttgtttgcctttg-3’,
and Probe #31; for OCT4 (114 bp): 5’-agcaaaacccggag-
gagt-3’,5 ’-ccacatcggcctgtgtatatc-3’, and Probe #35; for
GAPDH (66 bp): 5’-agccacatcgctcagacac-3’,5 ’-gcccaatac-
gaccaaatcc-3’, and Probe #60. The PCR reaction mixture
was incubated at 95°C for 10 min, followed by 35 cycles
of 95°C for 15 s, 60°C for 30 s and 72°C for 1 s. As posi-
tive control we used RNA purified from undifferentiated
human induced pluripotent stem cells. The amplification
of SOX2OT, ALX4 and ACTIN genes was achieved with
SYBR-Green (Eurogentec) and the following primer
pairs: For SOX2OT (76 bp): 5’-tccatggaatgaatgaaatgtt-3’,
5’-cagcctccaagacctagcc-3’;f o rALX4 (99 bp): 5’-tggccat-
gaggacagacc-3’,5 ’-gctgcatctgcccaaaac-3’;f o rACTIN (86
bp): 5’-agtcctgtggcatccacgaaacta-3’,5 ’-cactgtgttggcgta-
caggtcttt-3’. The PCR reaction mixture was incubated at
95°C for 10 min, followed by 40 cycles of 95°C for 15 s,
60°C for 1 min and a melting curve 40 - 95 °C for 1 s.
RNA purified from undifferentiated human induced plur-
ipotent stem cells was used as a positive control.
Statistical Analysis
To test associations between categorical variables, we
used the Chi square and Fisher’s exact test. Values of p
<0 . 0 5w e r ec o n s i d e r e ds i g n i ficant. All tests were two-
tailed and 95% confidence intervals were adopted. The
analyses were carried out using the SPSS 12.0 for Win-
dows statistical program (SPSS Inc., Chicago, IL).
Results
SOX2 expression in early-stage breast cancer
95 patients yielded material that could be analyzed
immunhistochemically for SOX2 expression. Human
squamous lung cancer samples were used as positive
controls for immunohistochemical detection of SOX2
expression [20]. Four expression scores were defined in
order to distinguish SOX2 negative and positive sam-
ples, and among latter the subgroup of SOX2 high
expressors (Figure 1A). Considering cases with any
SOX2 expressing cells as positive (score 0 vs. score 1-3)
nuclear SOX2 expression was detected in 24 out of 86
analyzed samples of invasive breast carcinoma and 4 out
of 9 DCIS (Table 1). Of note, while numbers of positive
cells were highly variable, the expression showed com-
parable strong intensity among samples and was mostly
restricted to the nucleus, as previously reported in
embryonic stem cells. Thus, intensity and localization of
the positive signal was not introduced as a variable in
the applied scoring system. Representative stainings for
tumors belonging to each score group are shown in
comparison to healthy breast tissue (Figure 1).
Correlation between SOX2 expression and
clinicopathological characteristics
Our comparative study of SOX2 negative and positive
tumors did not show significant correlations between
the SOX2 expression status and other tumor parameters
such as grading, breast cancer subtype, hormone recep-
tor or HER2 expression, or presence of lymphangiosis.
A trend to larger tumor size (p = 0.073) and to a histol-
ogy other than of ductal or lobular type was noted in
SOX2 expressors (p = 0.053; Table 2). Interestingly, if
high SOX2 expressors (score 3) were analyzed separately
and compared to the rest of the group (score 0 to 2),
they displayed significantly more often lymph-node
metastases (p = 0.018) and larger primary tumors (p =
0.047; Figure 2; Table 3). Although larger numbers are
required to analyze expression in DCIS, our data indi-
cate that SOX2 is expressed already aberrantly in DCIS
and therefore may be an early event in disease
progression.
SOX2 FISH and gene expression analysis in primary
tumors
Eleven SOX2 positive samples (7 belonging to expression
score 3 and 4 of score 2), 4 SOX2 negative samples as well
as 3 lymph-node samples showing high SOX2 expression
(score 3) were analyzed by FISH to explore whether aber-
rant SOX2 expression is a result of gene amplification as
previously reported in other carcinomas [20]. Surprisingly,
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documented in a score 3 primary tumor, unlike reported
in other tumors, the majority of analyzed samples did not
show SOX2 gene amplifications, suggesting that at least in
part of the breast carcinomas expressing SOX2, the aber-
rant gene expression is driven by other mechanisms. To
explore whether SOX2 induction is part of a more general
reactivation of embryonic genes, we assessed co-expres-
sion of NANOG and OCT4 i nt h es a m et u m o r sb yp e r -
forming real-time PCR analysis and using human
pluripotent stem cells as positive controls [17]. Among
fresh frozen samples collected prospectively from n = 18
patients we observed various degrees of SOX2 gene
expression (Figure 3), confirming our immunohistochem-
ical data. However, samples showing more pronounced
SOX2 expression levels (sample 1, 3 and 10) displayed sub-
stantial co-expression of OCT4 and NANOG (Figure 3).
Furthermore, co-expression with the previously described
SOX interacting gene ALX4 as well as with the SOX2-
overlapping transcript (SOX2OT) could be documented in
Table 2 Correlation of SOX2 score and clinicopathological parameters
SOX2
N total Negative Score 0 Positive Score 1-3 p-value
Tumor size
pT1 59 46 (78%) 13 (22%) 0.073
pT2 to pT4 27 16 (59%) 11 (41%)
Nodal status
Node-negative 62 44 (71%) 18 (29%) 0.789
Node-positive 23 17 (74%) 6 (26%)
Histology
Ductal 76 49 (73%) 18 (27%)
Lobular 11 10 (91%) 1 (10%) 0.053
Others 8 5 (38%) 5 (63%)
Grading
I-II 60 45 (75%) 15 (25%) 0.361
III 26 17 (65%) 9 (35%)
Lymphovasc. inv.
Negative 63 48 (76%) 15 (24%) 0.161
Positive 23 14 (61%) 9 (39%)
ER status
Negative 17 12 (71%) 5 (29%) 0.877
Positive 69 50 (73%) 19 (28%)
PR status
Negative 22 16 (73%) 6 (27%) 0.939
Positive 64 46 (72%) 18 (28%)
HER2
Negative 75 55 (73%) 20 (27%) 0.503
Positive 11 7 (64%) 4 (36%)
Subtype
Luminal A/B * 73 53 (73%) 20 (27%)
HER2 subtype 6 4 (67%) 2 (33%) 0.952
Triple negative 7 5 (71%) 2 (29%)
*Luminal A tumors are defined as tumors with expression of one or both hormone receptors without overexpression of Her2; Luminal B tumors express one or
both hormone receptors and show also Her2 overexpression.
Table 1 SOX2 expression in primary carcinoma (DCIS and invasive carcinoma) and lymph node samples
N total Score 0 Score 1 Score 2 Score 3
DCIS 9 5 (55.6%) 1 (11.1%) 2 (22.2%) 1 (11.1%)
Invasive Carcinoma 86 62 (72%) 11 (12.8%) 5 (5.8%) 8 (9.3%)
Lymph nodes 18 9 (50%) 4 (22.2%) 1 (5.5%) 4 (22.2%)
DCIS: ductal carcinoma in situ.
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[21,22].
Higher SOX2 expression in metastatic lymph nodes
To further dissect whether SOX2 plays a role in devel-
opment of metastases, we analyzed SOX2 expression in
metastatic lymph nodes. 23 out of 86 patients with inva-
sive primary tumors showed lymph node metastases,
out of which 18 yielded material that could be analyzed
for SOX2 expression (Table 1, Figure 2). The remaining
5 cases only presented with positive sentinel lymph-
nodes, which had been completely analyzed in step sec-
tions, and thus no material for additional SOX2 analysis
was available. As expected, SOX2 expression was
detected in all lymph-nodes from SOX2 positive primary
tumors (Figure 2A-B). Interestingly, SOX2 was addition-
ally detected in lymph-nodes derived from primary
tumors devoid of SOX2 expression (Figure 2B and 2D)
while no case could be detected where SOX2 was
expressed only in primary but not in metastatic cells.
Thus, the frequency of SOX2 positive samples in lymph
nodes was significantly higher than those of primary
tumors (p = 0.0432; Figure 2B). Of note, 3 out of 9 posi-
tive lymph nodes showed very high expression in nearly
all tumor cells, while such high expression was only
observed in 1 out of 24 positive primary tumors.
Discussion
SOX2, NANOG and OCT3/4 form the core of the self-
renewal transcription network in embryonic stem cells.
Figure 2 SOX2 expression in primary tumors and corresponding metastatic lymph nodes. (A) SOX2 is expressed in a higher percentage
of metastatic lymph nodes as compared to primary tumors; (B) Development of SOX2 expression in lymph nodes in comparison to the
corresponding metastatic primary tumor investigated in 18 samples. Positive SOX2 expression was detected in lymph node metastases
originating from both SOX2 positive or negative primary tumors while no loss of SOX2 positivity was observed during progression from primary
tumor to metastasis (C) Representative immunohistochemical staining of SOX2 in a primary tumor and the corresponding lymph node. Pictures
were taken with 200X magnification.
Table 3 SOX2 high expressors (Score 3) versus negative
or low (Score 0-2)
p-value
Tumor size 0.047
Nodal Status 0.018
Histology 0.272
Grading 0.252
Lymphovascular Invasiveness 0.470
ER Status 0.140
PR Status 0.373
Subtype 0.456
ER: Estrogen Receptor; PR: Progesteron Receptor.
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protein complexes [20], and furthermore are transcrip-
tionally interconnected and co-occupy promoters of
numerous target genes [23-26]. On a functional level,
selective downregulation of one of these factors induces
embryonic stem cell differentiation and exit from the
pluripotent stem cell state. More recently, combinatorial
overexpression of OCT4, SOX2, NANOG and others
was shown to reprogram several types of adult somatic
cells to a pluripotent stem cell like state [17,27,28]. In
these experiments, cells were reprogrammed fully or
only partially [29] possibly through heterogeneous expo-
sure to reprogramming factors. It is tempting to specu-
late that acquisition or overexpression of individual
factors (i.e. by chromosomal gain, as described in some
tumors), can promote tumorigenesis by processes
resembling partial reprogramming [17,29].
In our study we have focused on SOX2, a member of
the SOX (SRY-related HMG-box) family of transcription
factors. SOX proteins are expressed during early embry-
ogenesis and play important roles in embryonic and
extra-embryonic cell types [30]. To our knowledge there
is no data indicating a specific role of SOX2 during
breast tissue development and as far no relevant SOX2
expression could be detected in healthy human breast
specimens [14]. However, SOX2 expression was
described in a smaller percentage (16.7%) of lymph-
node negative breast carcinomas, suggesting a role in
breast tumorigenesis.
Breast cancer is a heterogeneous disorder presenting
in a variety of pathological entities and clinical manifes-
tation ranges. Based on molecular profiling and gene
expression signatures, five groups of breast cancers with
distinct prognostic and predictive significance have been
identified: basal-like, luminal A and B, HER2+ and nor-
mal breast-like carcinomas [31]. Of these, the most
malignant phenotype is shown by the basal-like cancers
encompassing high grade tumors negative for estrogen
receptor (ER) or HER2 expression, which are associated
with a tendency to visceral metastasis especially to the
lung and the brain and which also have the most repro-
ducible gene expression pattern across different studies
and technical platforms [32-35]. Among sporadic can-
cers, basal-like tumors are showing most genetic and
phenotypic similarities to the aggressive tumors arising
in BRCA1 germ line mutation carriers [32-34,36-39].
Consistently, 3q gains are most frequently observed in
tumors arising in BRCA1 mutation carriers [40,41] and,
among sporadic cancers, seen with highest incidence in
basal-like tumors (20% of cases, in comparison to 10%
of luminal tumors [42]).
In squamous lung and esophageal cancers, aberrant
SOX2 expression was linked to the genomic amplifica-
tion of its chromosomal location on chromosome
3q26.33. 3q copy number gains are a common event in
breast cancers and have been implicated as an indepen-
dent predictor of poor prognosis in node-negative breast
cancers [43]. A previous immunohistochemical study
performed in a cohort of lymph-node negative patients
observed predominant SOX2 expression in tumors with
basal-like phenotype [15], consistent with the pattern
described for 3q chromosomal gain. In our study on a
cohort of postmenopausal patients displaying both nega-
tive and positive lymphonodal status we could confirm
the aberrant expression of SOX2 in breast cancer. Inter-
estingly, we assessed a higher overall incidence of SOX2
expression than reported by the previous study (ca.
28%). This could be due to technical details and differ-
ent sensitivities of immunohistochemistry protocols,
although similar methods and the same cut-off defini-
tion for SOX2 positivity were applied. A more plausible
explanation is that inclusion of lymph-node positive
patients in our cohort may have enriched for samples
Figure 3 Gene expression of SOX2, NANOG and OCT4 in
different tumor samples shows clustering of embryonic factors
in certain tumors. Real-time PCR for SOX2, NANOG and OCT4 was
performed on isolated RNA from tumor tissue. RNA from
undifferentiated human pluripotent stem cells was used as a
control. Shown are fold relative gene expression levels in
comparison to undifferentiated pluripotent stem cells. Experiments
have been performed in triplicates: error bars depict standard
deviations.
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could not verify the correlation between SOX2 expres-
sion status and breast cancer with basal-like features
that is triple negativity for hormone receptors and
HER2 [16], although associations with other parameters
reflecting tumor aggressiveness such as tumor size and
positive lymphonodal status were observed. Taken
together, these results suggest that aberrant SOX2
expression plays a broader role in breast cancer patho-
genesis, exerting effects also outside of the subgroup of
triple negative tumors. However, it is possible that
SOX2 expression is indeed particularly enhanced in tri-
ple negative tumors and that our analysis in a cohort of
postmenopausal patients, where this molecular subtype
is underrepresented, failed to detect this correlation
because of low numbers. While some (especially the 3q
positive basal-like tumors) may acquire SOX2 as a result
of gains in specific chromosomal regions, SOX2 expres-
sion may be also induced by other upstream mechan-
isms inducing a general reactivation of an embryonic
genetic program. In support of this hypothesis, FISH
analysis performed in representative primary tumor and
lymph node samples with high SOX2 expression in
most cases did not show amplification of the SOX2
locus. Furthermore, SOX2 was detected to express in
concert with other pluripotency factors in a cohort of
18 patients analyzed by real-time PCR analysis where
high SOX2 expressing samples were found to also
express higher levels of OCT4 and NANOG (Figure 3).
In vitro and in vivo tumorigenesis studies performed
with breast cancer cell lines link SOX2 expression to
early events in tumor development and potentially to
tumor invasiveness [14]. Similar properties have been
s h o w ni nl u n gs q u a m o u sc e l lc a r c i n o m al i n e sw h e r ein
vitro studies suggest SOX2-mediated induction of cell
proliferation and anchorage independent growth
[11,12,14]. Although SOX2 functions differ between
organ systems since transcriptional activation is influ-
enced by the recruitment of tissue-specific transcription
factors [44], SOX2-mediated induction of tumor inva-
siveness may be a common theme in different tumor
entities [45]. To further explore these findings in breast
cancer, we performed correlations between SOX2
expression levels and lymphonodal status and explored
expression of SOX2 in metastatic lymph nodes as well
as in earlier disease stages such as ductal carcinoma in
situ. Overall, our immunohistochemical study provides
evidence supporting an early role of SOX2 during dis-
ease pathogenesis, since similar expression levels were
found in DCIS and early-stage invasive tumors. How-
ever, expression was significantly higher in metastatic
lymph nodes supporting the notion that SOX2 plays a
role in disease invasiveness and progression. Since no
primary tumor expressing SOX2 produced a lymph-
node metastasis devoid of SOX2 expression and SOX2
positive lymph-nodes showed particularly high expres-
sion levels, we suggest that cells displaying SOX2
expression are enriched in metastatic potential and
SOX2 plays a specific role in the development of lymph-
node metastases. However, further studies are needed to
deepen our understanding of SOX2 and other embryo-
nic factors during mammary tumorigenesis and larger
numbers of prospectively collected samples should be
screened before proposing SOX2 as a predictor of lym-
phonodal status in breast cancer.
Conclusions
The embryonic stem cell factor SOX2 is expressed in a
variety of early stage postmenopausal breast carcinomas
and metastatic lymph nodes. Our data suggest that
SOX2 plays an early role in breast carcinogenesis and
high expression may promote metastatic potential.
Further studies are needed to explore whether SOX2
can predict metastatic potential at an early tumor stage.
Additional material
Additional file 1: Supplementary Figure 1: Gene expression of
SOX2OT and ALX4 in fresh frozen tumor samples. Real-time PCR for
SOX2OT and ALX4 was performed on isolated RNA from tumor tissue.
RNA from undifferentiated human pluripotent stem cells was used as a
control. Shown are fold relative gene expression levels in comparison to
undifferentiated pluripotent stem cells.
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